SAN DIEGO, July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.
Webcast Details
The webcast can be accessed through the Events & Presentations section of Illumina's Investor Relations website at investor.illumina.com. We recommend that participants pre-register for the event on our website or using the following link: Illumina 2024 Strategy Update Registration. A replay will be posted on Illumina's Investor Relations website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube
Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
Media:
Bonny Fowler
+1.740.641.5579
pr@illumina.com
View original content:
SOURCE Illumina, Inc.
正如 Illumina, Inc. (纳斯达克代码:ILMN) 公司先前于2024年6月24日所宣布的,公司将于2024年8月13日星期二早上8:00太平洋时间开始举行策略更新活动。该活动将由 Illumina 执行团队的成员进行演讲,并在问答环节结束。
网络研讨会细节
网络直播可通过 Illumina 的投资者关系网站(investor.illumina.com)的 事件和演示文稿 部分进行访问。我们建议参与者使用我们的网站或以下链接预先注册,以便参加此活动:Illumina 2024 策略更新注册。活动后,回放将发布在Illumina的投资者关系网站上,并且将可供至少30天。
关于Illumina
Illumina通过解锁基因组的力量来提高人类健康水平。我们专注于创新,在DNA测序和基于阵列的技术方面,已被确认为全球领先者,在生命科学,肿瘤学,生殖健康,农业和其他新兴领域为客户服务。我们的产品用于生命科学,肿瘤学,生殖健康,农业和其他新兴应用领域。要了解更多信息,请访问illumina.com,并在X(Twitter),Facebook,LinkedIn,Instagram,TikTok和YouTube上与我们联系。
投资者:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
媒体:
Bonny Fowler
+1.740.641.5579
pr@illumina.com
查看原始内容:
来源: Illumina, Inc.